Personalized Obesity Treatment System with Integrated Technologies

A novel system integrating wearable devices, machine learning algorithms, blockchain technology, novel nanoparticle delivery systems, IoT-enabled biosensors, and artificial intelligence to provide personalized and optimized treatment for obesity and lipid-related metabolic disorders.

The original patent disclosed a functional composition for preventing or treating obesity or lipid-related metabolic disease using irosustat. However, the patent's limitations include the lack of personalized treatment approaches, inefficient data management, and limited biomarker detection capabilities. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

The system comprises a wearable device for tracking physical activity and caloric intake, which is analyzed by a machine learning algorithm to predict optimal irosustat dosages. A mobile application transmits these dosages to a patient's healthcare provider. Additionally, the system incorporates blockchain technology to store patient data and treatment outcomes on a decentralized ledger, triggering alerts and notifications for healthcare providers. The composition further includes a novel nanoparticle delivery system engineered to target specific tissues and increase bioavailability. An IoT-enabled biosensor is used for real-time detection of lipid-related metabolic disease biomarkers, which are integrated with electronic health records on a cloud-based analytics platform. Finally, artificial intelligence is used to predict obesity treatment outcomes by training a deep learning model on a dataset of patient characteristics and treatment responses.

The new claims introduce a synergistic combination of technologies that provides a personalized and optimized treatment approach, which is not obvious from the original patent. The integration of wearable devices, machine learning algorithms, blockchain technology, novel nanoparticle delivery systems, IoT-enabled biosensors, and artificial intelligence creates a new and non-obvious system for treating obesity and lipid-related metabolic disorders.

Alternative embodiments may include using different types of wearable devices or biosensors, varying the machine learning algorithm or blockchain technology, or incorporating additional technologies such as augmented reality or natural language processing. Variations may also include applying the system to other diseases or conditions, such as cardiovascular disease or metabolic syndromes.

The inventive concept has significant commercial potential in the healthcare and pharmaceutical industries, particularly in the areas of personalized medicine and precision health. The system's ability to provide optimized treatment approaches and improve patient outcomes could lead to increased adoption and revenue growth in these markets.